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RORct+ innate lymphoid cells (ILCs), or ILC3, play a fundamental role in the development of
lymphoid tissues, as well as in homeostasis and defence of mucosal tissues. These cells produce
IL-22, IL-17A and LTa1b2, key cytokines for the activation of epithelial defences and the recruitment
of polymorphonuclear phagocytes. In the absence of ILC3, the early defence to infection and
resistance to injury are compromised. Given the importance of ILC3 in mucosal immunity,
signiﬁcant efforts are made to discover their multiple functions and decipher their mode of action
and regulation.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction recruitment of lymphocytes to the developing lymphoid tissuesILCs have only recently been recognized as a major population
of immune effector cells through the discovery of new subsets
and the demonstrations that early responses to infections are
largely dependent on cytokines they produce [1–3]. ILCs are
deﬁned by their developmental origin from the common lymphoid
progenitor that also gives rise to B and T cells. However, ILCs do not
express an antigen receptor, and therefore, do not undergo clonal
selection and expansion as lymphocytes do. Rather, ILCs react to
cytokines and chemokines produced in tissues following infection
and injury, and respond by expansion and the production of
effector cytokines.
The ﬁrst type of ILCs described more than 30 years ago is
natural killer (NK) cells, innate cells that, similar to CD8+ cytolytic
T cells, lyse target cells and produce IFNc [4]. More recently,
IFNc-producing yet non-cytolytic ILCs, similar to T helper (Th) 1
cells, were described to reside in the mucosal epithelium [5]. In
the 1990s, another lymphoid cell type that did not express an
antigen receptor was found colonizing nascent lymph nodes and
Peyer’s patches, or lymphoid tissue anlagen [6,7]. These cells were
termed lymphoid tissue inducer (LTi) cells, shown to be required
for the activation of local stromal cells and the subsequent[8]. After birth, LTi cells cluster into cryptopatches in the intestinal
lamina propria and induce the formation of isolated lymphoid fol-
licles (ILFs) [9–11]. In 2008, it was found that LTi cells are members
of a larger family of LTi-like ILCs that express pro-inﬂammatory
cytokines, such as IL-17A and IL-22, playing a role in mucosal
homeostasis and defence similar to Th17 cells [12–16]. Finally, a
third subset of ILCs was discovered to duplicate the activity of
Th2 cells in the production of IL-4, IL-5, IL-6 and IL-13, and to be
involved in early defence against worms and in allergic responses
[17–19]. Altogether, ILCs are grouped into three categories
according to their cytokine expression pattern mirroring the
activity of Th cells: type 1, 2 and 3 ILCs, also termed ILC1, ILC2
and ILC3, reﬂecting Th1, Th2 and Th17 cells [1].
With the exception of LTi cells, ILCs were ﬁrst described in the
context of infection and inﬂammation, during which they expand
from initially small populations, or at steady state in the intestine
where they establish a dynamic crosstalk with the resident
microbiota. Even though the generation of LTi cells is programmed
[20,21], the differentiation, expansion and activity of LTi cells, and
of ILCs in general, is closely linked to the microbial environment
and the local perturbation induced by infection and injury. The
identiﬁcation of microbes and molecules involved in this crosstalk
are subject of intense investigation as they may hold keys to the
control of early immunity to infection and injury, and thus to the
regulation of the developing adaptive immune response.
In this review, we will focus on the development, subset analy-
sis and regulation of ILC3, which are dependent on expression of
the nuclear hormone receptor RORct [22].
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All ILCs are derived from common lymphoid progenitors, which
arise from fetal liver or bone marrow hematopoietic stem cells
[1,2]. Sequential expression of transcription factors and cytokine
receptors orchestrates the commitment of multi-potent progeni-
tors towards the ILC3 cell fate [3]. This developmental program is
framed by interactions with environmental cues such as Notch
ligands and components of the intestinal microbiota that could
also account for some degree of plasticity among ILC3 subsets
(see Fig. 1).
A common requirement for the development of lymphoid cells
is activation of the IL-7 receptor a (IL-7Ra). The common lymphoid
progenitor is dependent on IL-7Ra, and mice deﬁcient in IL-7Ra or
in the common cc chain associated with its signalling are charac-
teristically lymphopenic [23]. The ﬁrst step in the differentiation
of the common lymphoid progenitor to ILCs is the expression of
the inhibitor of DNA binding Id2 [1,22,24]. In the absence of Id2,
ILCs fail to develop as the common lymphoid progenitor is induced
by E-box transcription factors to generate lymphocytes. Id2 blocks
these E-box proteins, and an absence of both Id2 and the E-box
protein E2A restores ILC development [25]. However, Id2 is not a
marker of ILCs, as it is also expressed in mature T cells and is
involved in the generation of memory cells [26]. Another transcrip-
tion factor, Gata3, initially shown to be speciﬁcally required for the
development of ILC2 [27–29], also appears to play a more general
role in the early differentiation of ILC3 [30].
Another hurdle facing the development of ILCs from the com-
mon lymphoid progenitor is the early bias towards B cell differen-
tiation. The presence of Notch ligands, at least in some niches of
the fetal liver and the bone marrow after birth, blocks this bias
and allows both the development of T cells and ILCs [31]. However,
the prolonged presence of Notch ligands subsequently favours the
emergence of T cells over ILCs, as in the thymus. As a consequence,
immature thymocytes grown in vitro in the absence of Notch
ligands generate signiﬁcantly higher frequencies of ILCs [31].Fig. 1. The development of ILC3. In the fetus, common lymphoid progenitors (CLP) gener
block the generation of B and T cells. Notch signalling blocks the generation of B cells, bu
thymus. The development of ILC3 speciﬁcally requires RORct, while Gata3 is involved i
additional subset of ILC3 that does not express CCR6 and does not induce lymphoid tiss
ILC3 become dependent on the aryl hydrocarbon receptor (Ahr) that binds dietary metab
ILC3 precursors generate T-bet+ cells that not only express IL-17 and IL-22, but also IF
common precursor to ILC1, ILC2 and CCR6 ILC3 [37].Once progenitors are solidly engaged into the ILC pathway, the
decision has to be taken to generate one of the at least 3 types of
ILCs. The transcription factors shown to be required for the
differentiation of Th cells are also required, but not necessarily
sufﬁcient, for the differentiation of the ILCsubsets. T-bet is required
to generate Th1 cells and ILC1 [5,32,33], Gata3 is required to gen-
erate Th2 cells and ILC2 [27–29], and RORct is required to generate
Th17 cells and ILC3 [22,34]. In mice deﬁcient for RORct, ILC3 do not
develop, leading to a lack of all lymph nodes and Peyer’s patches
[22]. How the expression of RORct is induced in ILC precursors
remains unclear. In the differentiation of Th17 cells from naïve
CD4+ ab T cells, RORct is induced through the activation of Stat3
by cytokines such as IL-6 and IL-23, in combination with TGFb
signalling [35]. However, the involvement of these cytokines in
the generation of LTi cells can be excluded as mice deﬁcient in
Stat3 in the hematopoietic lineage still develop lymph nodes and
Peyer’s patches. The lineage-speciﬁc transcription factors are sta-
bly expressed in their respective Th cells and ILCs, and are there-
fore used as speciﬁc markers. However, lineage plasticity has
been observed in both T cells and ILCs. For instance, inﬂammatory
settings induce a subset of ILC3 to downregulate RORct, upregulate
T-bet and express IFNc [33], even though it remains to be assessed
whether mature ILC3 or RORct+ immature precursors develop an
ILC1 phenotype. The transcription factor Tcf-1 is required for fur-
ther differentiation of ILC3 into one particular subset expressing
the pan-NK marker NKp46 (see below) [36]. Finally, a recent study
suggests that the development of ILC3 is not as linear as described
here, as an ILC precursor expressing the transcription factor PLZF
gives rise to ILC1, ILC2 and ILC3 but not to LTi cells [37].
The impact of the microbiota on the generation of ILC3 remains
controversial. Whereas the generation of LTi cells in the fetus is
obviously independent of microbiota [20,21], as well as of potential
microbial compounds delivered by the mother through the
placenta (our own unpublished data), the generation of ILC3 after
birth may be induced by certain types of microbiota, as reported
by some laboratories [13,15]. Clearer is the impact of nutrientsate LTi cells, half of which express CD4. The development of all ILCs requires Id2 to
t subsequently, favours precursors to generate T cells instead of ILCs, such as in the
n the development of both ILC3 and ILC2. After birth, ILC3 precursors generate an
ue formation, including Tcf-1-dependent NKp46+ cells. Furthermore, LTi and CCR6
olites, as well as on vitamin A. In the context of inﬂammation, CCR6NKp46 ILC3 or
Nc. Recent data suggest that the development of LTi cells branches off before the
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hydrocarbon receptor Ahr, required for the generation of T cells
producing IL-22 [38], show a deﬁcit in the formation of ILFs, but
not in the development of lymph nodes and Peyer’s patches [39–
41]. Ahr appears to be required for the maintenance of ILC3 subsets
after, but not before birth, as ligands for Ahr are provided through
food by cruciferous vegetables, such as broccoli and Brussel’s
sprouts. Another nutrient required for the generation of ILC3 is
vitamin A. In its absence, precursors develop preferentially into
ILC2, thus linking vitamin A and nutrition to the regulation of
intestinal immunity [42].
3. Subsets and functions of RORct+ ILCs
Whereas LTi cells are programmed to develop in the fetus, an-
other subset of LTi-like ILC3 develops mostly after birth (Fig. 2)
[20]. By weaning it becomes the major subset of ILC3 in the intes-
tinal lamina propria. These LTi-like cells do not express the chemo-
kine receptor CCR6 [20], required for LTi cells to cluster after birth
in cryptopatches to form ILFs. CCR6 ILC3 rather resemble lym-
phoid effector cells and produce high amounts of cytokines includ-
ing IL-22 [13,21]. To further add some complexity so typical of
immunology, both CCR6+ and CCR6 ILC3 can be further subdi-
vided into phenotypically and functionally distinct types of cells.
LTi cells, the ﬁrst ILC3 to be characterized [6,7,22], can be subdi-
vided into CD4+ (LTi4) and CD4 (LTi0) cells, which reside in lym-
phoid tissues at a ratio of roughly 1 to 1, depending on the tissue
and age of mice. It has been suggested that LTi0 cells are precursors
to mature LTi4 cells, even though the level of effector cytokines,
including IL-17A and IL-22, is similar between the two cell types
[21]. The role of CD4 remains unknown, as the development of lym-
phoid tissues proceeds normally in CD4-deﬁcient mice. LTi cells
also express high levels of MHC class II, involved in the regulation
of T cells reacting to the microbiota [43]. However, a link between
the expression of CD4 and MHC class II by LTi cells has not been
established. Both subsets express lymphotoxin (LT) a1b2, which
activates LTbR+ stromal cells to produce cytokines, such as CXCL13,
and to express the adhesion molecules ICAM-1 and VCAM-1, to re-
cruit further waves of LTi, as well as B and T cells [8,44]. A similarFig. 2. Subsets and functions of ILC3. Three types of functions are provided by ILC3: the in
by IL-17 and IL-22, and anti-bacterial defence induced by IFNc in the context of infectio
functions: LTi cells that express CCR6 and cluster to induce the development of lymphoi
effector T cells. Both CCR6+ and CCR6 cells express IL-22 and IL-17 before weaning an
(double negative or ‘‘DN’’ ILC3) include effectors that express IL-22, as well as precursors t
population of DN ILC3 also expands during colitis that expresses IL-17, IL-22 and IFNc. Th
the latter may include both mature effectors and immature precursors.pathway unfolds in the formation of ILFs after birth, although this
process requires the colonization of the intestine by bacteria and
the induction of CCL20 production by epithelial cells, the ligand of
CCR6 on LTi and B cells [9]. After birth, LTi cells are also involved
in the IL-22 mediated defence against intestinal pathogens, such
as the Proteobacteria Citrobacter rodentium [45].
Within CCR6 ILC3, the subset of NKp46+ cells, and their human
NKp44+ counterparts, gained much attention through their identi-
ﬁcation as a population of NK-like cells expressing RORct and IL-22
[13–16,46]. NKp46+ ILCs are abundant in the intestine and play a
major role in intestinal defence against infection by C. rodentium
as well as in resistance to injury and microbial invasion induced
by dextran sodium sulfate (DSS). The functional signiﬁcance of
NKp46 expression on ILC3 remains unclear [47], even though
receptors of this family of natural cytotoxicity receptors are in-
volved in the regulation of the activity of NK cells [48,49]. During
infection and inﬂammation, NKp46+ ILC3 expand that also express
T-bet and IFNc, therefore closely resembling ILC1 [33].
A more cryptic subset of CCR6 ILC3 is deﬁned mostly by neg-
ative staining for CD4, NKp46, as well as low levels of IL-7Ra
[20,21]. This subset was found to express transcripts coding for
CD3 chains but no protein. It was also found to generate IFNc-pro-
ducing ILCs, as mentioned above [33]. Furthermore, a subset of IL-
17A-, IL-22- and IFNc-producing CCR6 NKp46 ILC3 was ex-
panded in the inﬂamed colon in both mouse and human [50]. It
is likely that the ill-deﬁned population of CCR6 NKp46- ILC3 is a
heterogeneous mix of progenitor and effector cells. A more detailed
analysis of this population of ILC3 is warranted, as it is a subset of
abundant ILC3 in the intestine of mice after weaning.
4. Regulation of RORct+ ILCs
LTi cells are the ﬁrst type of lymphoid cells to be generated dur-
ing fetal life [8,20]. Not only do they induce the formation of lym-
phoid tissues through the expression of LTa1b2 and other
members of the TNF superfamily, such as TRANCE, but they also
produce IL-22 and IL-17A [21]. The role of these cytokines during
fetal life is unknown, as mice deﬁcient for IL-22 or IL-17A develop
a normal set of lymphoid tissues. It is possible that this expressionduction of lymphoid tissue development through LTa1b2, mucosal defence induced
n and inﬂammation. ILC3 can be subdivided into two main subsets that share these
d tissues, and a diverse group of CCR6 cells that do not cluster but rather resemble
d during inﬂammation. CCR6 ILC3 that do not express the pan-NK marker NKp46
o NKp46+ cells that express T-bet and IFNc and expand during intestinal infection. A
e lineage relationship between IFNc-producing ILC3 and DN ILC3 remains unclear, as
Fig. 3. Regulation of ILC3. ILC3 are programmed to express IL-17 and IL-22, independently of the microbial environment and inﬂammation. For instance, the highest level of
ILC3 activity is found in fetal LTi cells. After birth, this activity is negatively regulated by microbiota that induces expression of IL-25 by epithelial cells. IL-25 acts on DCs to
regulate the activity of ILC3. The mechanisms by which microbiota induces IL-25 expression and DCs regulate ILC3 remain unknown. T cells are also found to regulate ILC3
activity, possibly through competition for cytokines such as IL-23. Of note, particular types of microbiota have been found to rather activate than regulate ILC3. In the context
of inﬂammation induced by epithelial damage or infection, the negative regulation of ILC3 is overridden by microbial signals, such as ﬂagellin and possibly ATP [59], which
activate CD11b+ DCs and macrophages to produce IL-23. Activated ILC3 provide a positive feedback loop by activating DCs through LTa1b2, and induce the production of anti-
microbial proteins by epithelial cells through IL-17, IL-22 and LTa1b2 [60], and the recruitment of neutrophils through IL-17.
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by RORct. However, it is more likely that IL-22 and IL-17A play a
role in the selection of bacteria colonizing the intestine after birth
by inducing anti-microbial peptides in epithelial cells [51]. Inter-
estingly, upon bacterial colonization of the intestine after birth,
the cytokine-producing activity of ILC3 is signiﬁcantly reduced as
compared to fetal production levels, a reduction that is alleviated
in germfree mice (Fig. 3) [21]. We showed that microbiota induces
the production of IL-25 by epithelial cells, which inhibits the
expression of IL-17A and IL-22 by a mechanism that involves den-
dritic cells (DC), thereby establishing a negative feedback loop on
the anti-bacterial activity of ILC3. Nevertheless, it has been ob-
served by other laboratories that the production of IL-22 was actu-
ally increased in the presence of microbiota, indicating that
different components of the microbiota have a positive or a nega-
tive effect on the activity of ILC3 [13,15]. In the context of colitis,
the activity of ILC3 is unleashed to levels similar to those found
during fetal life [21].
Dendritic cells (DCs) are an important element for the regulation
of ILC3 activity. DCs establish a link between microbiota and ILC3
through recognition of microbe-associated molecular patterns
(MAMPs). Infection by C. rodentium induces the production of
IL-23 by CD103+ CD11b+ DCs [52], as well as by CX3CR1+ DCs [53],
which then induce IL-22 production by ILC3. CD103+ CD11b+ DCs
also produce IL-23 upon recognition of ﬂagellin by TLR5, and induce
IL-22 production by ILC3 peaking within 2–3 h upon ﬂagellin
injection [54]. As ILC3 express LTa1b2 and DCs express LTbR, a
positive feedback loop is established where ILC3 further promote
DCs to produce IL-23 [55]. Direct activation of ILC3 by MAMPs has
been reported in the human system, where tonsil-derived ILC3
could be activated to produce diverse cytokines in response to
TLR2 stimulation [56], but such a pathway has not yet been reported
in mouse.
As ILC3 have functions similar to Th17 cells, it is expected that
activation of these two cell types involves competition for cytokines
such as IL-23. In the absence of T cells in RAG-1-deﬁcient mice, the
activity of ILC3 is increased [21,57], even though the mechanism of
this lymphocyte-mediated repression remains to be determined.
Conversely, ILC3 regulate CD4+ T cells through their expression ofMHC class II and the processing and presentation of microbiota-
derived antigens [43]. As a consequence, the selective deletion of
MHC class II in ILC3 leads to an increased reactivity of T cells against
the microbiota and the development of intestinal inﬂammation
[43]. Furthermore, ILC3 control the number of lamina propria T cells,
and as a consequence the production of T cell-dependent IgA,
through the expression of soluble LTa3 [58]. The mutual regulation
of T cells and ILCs, and their respective roles in immune defence, are
central questions that remain to be explored further. However, new
mouse models are needed that allow for the selective depletion of
ILC subsets without affecting the integrity of T cells.5. Conclusion
ILCs play a fundamental role early in immune responses. They
replicate the regulatory roles of Th cell subsets promptly after tis-
sue injury when T cells still need to be selected and expanded.
Therefore, knowing the rules that determine the development of
ILC1, ILC2 and ILC3 subsets, and regulation of their activity, should
allow to create immunotherapies, including vaccines, that are bet-
ter targeted to speciﬁc types of injury or infection. ILC biology may
thus lead to a new era of innate immunity for the control of adap-
tive immunity.Acknowledgements
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